• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Ardelyx Inc.

    2/14/25 12:57:20 PM ET
    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ARDX alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 5)


    Ardelyx Inc

    (Name of Issuer)


    Common Stock

    (Title of Class of Securities)


    039697107

    (CUSIP Number)


    12/31/2024

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    039697107


    1Names of Reporting Persons

    JANUS HENDERSON GROUP PLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    JERSEY
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    24,387,941.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    24,387,941.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    24,387,941.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    10.3 %
    12Type of Reporting Person (See Instructions)

    IA, HC


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Ardelyx Inc
    (b)Address of issuer's principal executive offices:

    34175 ARDENWOOD BLVD. FREMONT, CA 94555
    Item 2. 
    (a)Name of person filing:

    Janus Henderson Group plc
    (b)Address or principal business office or, if none, residence:

    201 Bishopsgate EC2M 3AE, United Kingdom
    (c)Citizenship:

    Y9
    (d)Title of class of securities:

    Common Stock
    (e)CUSIP No.:

    039697107
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    JHIUS may be deemed to be the beneficial owner of 24,136,606 shares
    (b)Percent of class:

    10.2  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    0

     (ii) Shared power to vote or to direct the vote:

    24136606

     (iii) Sole power to dispose or to direct the disposition of:

    0

     (iv) Shared power to dispose or to direct the disposition of:

    24136606

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    N/A
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.


    JHIUS, JHIUKL and JHIAIFML are indirect subsidiaries of Janus Henderson and are registered investment advisers furnishing investment advice to Managed Portfolios.
    Item 8.Identification and Classification of Members of the Group.
     
    If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group.


    N/A
    Item 9.Notice of Dissolution of Group.
     
    Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity. See Item 5.


    N/A

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    JANUS HENDERSON GROUP PLC
     
    Signature:Kristin Mariani
    Name/Title:Head of North America Compliance, CCO
    Date:02/14/2025
    Exhibit Information

    POWER OF ATTORNEY The undersigned, Janus Henderson Group plc ("the Company"), does hereby make, constitute and appoint each of Kristin Mariani and Caroline Barotti acting severally, as its true and lawful attorneys in-fact, for the purpose of, from time to time, executing in its name and on its behalf, whether the Company individually or as representative of others, any and all documents, certificates, instruments, statements, other filings and amendments to the foregoing (collectively, "documents") determined by such person to be necessary or appropriate to comply with ownership or control-person reporting requirements imposed by any United States or non-United States governmental or regulatory authority, including, without limitation, Forms 13D, 13F, 13G and 13H and any amendments to any of the foregoing as may be required to be filed with the Securities and Exchange Commission, and delivering, furnishing or filing any such documents with the appropriate governmental, regulatory authority or other person, and giving and granting to each such attorney-in-fact power and authority to act in the premises as fully and to all intents and purposes as the Company might or could do if personally present by one of its authorized signatories, hereby ratifying and confirming all that said attorney-in-fact shall lawfully do or cause to be done by virtue hereof. Any such determination by an attorney-in-fact named herein shall be conclusively evidenced by such person's execution, delivery, furnishing or filing of the applicable document. This power of attorney shall be valid from the date hereof and shall remain in full force and effect until either revoked in writing by the Company, or, in respect of any attorney-in-fact named herein, until such person ceases to be an employee of the Company or one of its affiliates. IN WITNESS WHEREOF, the undersigned has caused this power of attorney to be executed as of this 9th day of December, 2022. Janus Henderson Group plc By: /s/ Michelle Rosenberg Name: Michelle Rosenberg Title: General Counsel and Company Secretary

    Get the next $ARDX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ARDX

    DatePrice TargetRatingAnalyst
    5/2/2025$11.00Strong Buy → Outperform
    Raymond James
    3/7/2025Buy
    Ladenburg Thalmann
    3/4/2025$14.00Buy
    BTIG Research
    11/11/2024$11.00 → $5.50Buy → Neutral
    H.C. Wainwright
    7/2/2024$15.00 → $7.00Overweight → Neutral
    Piper Sandler
    4/5/2024$14.00Outperform
    Leerink Partners
    12/18/2023$12.00Strong Buy
    Raymond James
    9/7/2023$9.00Buy
    H.C. Wainwright
    More analyst ratings

    $ARDX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Ardelyx Inc.

      SC 13G/A - ARDELYX, INC. (0001437402) (Subject)

      11/14/24 4:08:33 PM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Ardelyx Inc.

      SC 13G/A - ARDELYX, INC. (0001437402) (Subject)

      7/10/24 6:32:11 AM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Ardelyx Inc. (Amendment)

      SC 13G/A - ARDELYX, INC. (0001437402) (Subject)

      2/13/24 5:26:59 PM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARDX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Mott David M bought $1,610,936 worth of shares (381,377 units at $4.22), increasing direct ownership by 19% to 2,396,871 units (SEC Form 4)

      4 - ARDELYX, INC. (0001437402) (Issuer)

      5/5/25 8:22:23 PM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Mott David M bought $388,738 worth of shares (77,729 units at $5.00), increasing direct ownership by 4% to 2,015,494 units (SEC Form 4)

      4 - ARDELYX, INC. (0001437402) (Issuer)

      2/26/25 7:21:25 PM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Mott David M bought $992,672 worth of shares (199,000 units at $4.99), increasing direct ownership by 11% to 1,937,765 units (SEC Form 4)

      4 - ARDELYX, INC. (0001437402) (Issuer)

      1/22/25 5:25:52 PM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARDX
    SEC Filings

    See more
    • SEC Form 144 filed by Ardelyx Inc.

      144 - ARDELYX, INC. (0001437402) (Subject)

      5/2/25 4:22:02 PM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Ardelyx Inc.

      10-Q - ARDELYX, INC. (0001437402) (Filer)

      5/1/25 4:04:48 PM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ardelyx Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - ARDELYX, INC. (0001437402) (Filer)

      5/1/25 4:03:36 PM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARDX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more

    $ARDX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • FDA Approval for XPHOZAH issued to ARDELYX INC

      Submission status for ARDELYX INC's drug XPHOZAH (ORIG-1) with active ingredient TENAPANOR has changed to 'Approval' on 10/17/2023. Application Category: NDA, Application Number: 213931, Application Classification: Type 10 - New Indication Submitted as Distinct NDA - Not Consolidated

      10/20/23 4:37:52 AM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for XPHOZAH issued to ARDELYX INC

      Submission status for ARDELYX INC's drug XPHOZAH (ORIG-1) with active ingredient TENAPANOR has changed to 'Approval' on 10/17/2023. Application Category: NDA, Application Number: 213931, Application Classification: Labeling

      10/18/23 4:43:04 PM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for XPHOZA™ issued to ARDELYX INC

      Submission status for ARDELYX INC's drug XPHOZA™ (ORIG-1) with active ingredient TENAPANOR has changed to 'Approval' on 10/17/2023. Application Category: NDA, Application Number: 213931, Application Classification: Labeling

      10/18/23 4:37:08 PM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ardelyx downgraded by Raymond James with a new price target

      Raymond James downgraded Ardelyx from Strong Buy to Outperform and set a new price target of $11.00

      5/2/25 8:06:00 AM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ladenburg Thalmann resumed coverage on Ardelyx

      Ladenburg Thalmann resumed coverage of Ardelyx with a rating of Buy

      3/7/25 8:02:22 AM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BTIG Research initiated coverage on Ardelyx with a new price target

      BTIG Research initiated coverage of Ardelyx with a rating of Buy and set a new price target of $14.00

      3/4/25 7:19:29 AM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARDX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Ardelyx Presents Data Supporting IBSRELA® (tenapanor) at Digestive Disease Week 2025 Conference

      WALTHAM, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that the company presented data supporting the company's first-in-class retainagogue, IBSRELA® (tenapanor), as well as results from the IBS in America 2024 supplemental survey, at the Digestive Disease Week Conference (DDW), now underway in San Diego. IBSRELA is approved by the U.S. Food and Drug Administration to treat irritable bowel syndrome with constipation (IBS-C) in adults. "Ardelyx is committed to continuing to grow

      5/6/25 8:01:45 AM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ardelyx Reports First Quarter 2025 Financial Results and Provides Business Update

      Company reports $74.1 million in Q1 total revenue, reflecting 61% growth year-over-year IBSRELA net product sales revenue of $44.4 million; XPHOZAH net product sales revenue of $23.4 million  Company ends Q1 with $214.0 million in cash, cash equivalents and investments Conference call scheduled for 4:30 PM Eastern Time WALTHAM, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today reported financial results for the first quarter ended March 31, 2025 and provided a business update. "Ardelyx deliver

      5/1/25 4:01:51 PM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ardelyx Appoints Merdad Parsey, M.D., Ph.D. to its Board of Directors

      WALTHAM, Mass., April 29, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced the appointment of Merdad Parsey, M.D., Ph.D. to the company's board of directors. "We are thrilled to welcome Merdad to our board of directors," said Mike Raab, president and chief executive officer of Ardelyx. "Merdad is a veteran biotech leader and clinician with a commitment to patients that aligns with the Ardelyx vision of a healthier tomorrow for patients. His broad leadership experience spans the entire pharmaceutical d

      4/29/25 8:00:00 AM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARDX
    Financials

    Live finance-specific insights

    See more
    • Ardelyx Reports First Quarter 2025 Financial Results and Provides Business Update

      Company reports $74.1 million in Q1 total revenue, reflecting 61% growth year-over-year IBSRELA net product sales revenue of $44.4 million; XPHOZAH net product sales revenue of $23.4 million  Company ends Q1 with $214.0 million in cash, cash equivalents and investments Conference call scheduled for 4:30 PM Eastern Time WALTHAM, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today reported financial results for the first quarter ended March 31, 2025 and provided a business update. "Ardelyx deliver

      5/1/25 4:01:51 PM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ardelyx to Report First Quarter 2025 Financial Results on May 1, 2025

      WALTHAM, Mass., April 17, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced it will hold a conference call on Thursday, May 1, 2025, at 4:30 p.m. Eastern Time to discuss financial results and provide a business update from the first quarter of 2025. To participate in the conference call, please dial (877) 346-6112 (domestic) or (848) 280-6350 (international) and ask to be joined into the Ardelyx call. Live audio of the conference call will be simultaneously webcast and will be available under the Inves

      4/17/25 8:00:56 AM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ardelyx Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

      Company achieved significant commercial progress in 2024, finishing with total revenue of $333.6 million, including $319.2 million in U.S. Net Product Sales Company reaffirms combined peak sales of IBSRELA and XPHOZAH of $1.75 Billion Company ended FY 2024 with $250.1 million in cash, cash equivalents and investments Conference call scheduled for 8:00 AM Eastern Time WALTHAM, Mass., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today reported financial results for the fourth quarter and full year ended

      2/20/25 7:30:54 AM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARDX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Mott David M bought $1,610,936 worth of shares (381,377 units at $4.22), increasing direct ownership by 19% to 2,396,871 units (SEC Form 4)

      4 - ARDELYX, INC. (0001437402) (Issuer)

      5/5/25 8:22:23 PM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President & CEO Raab Michael sold $177,168 worth of shares (41,666 units at $4.25) and exercised 20,833 shares at a strike of $0.99, decreasing direct ownership by 1% to 1,594,754 units (SEC Form 4)

      4 - ARDELYX, INC. (0001437402) (Issuer)

      5/5/25 8:14:10 PM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President & CEO Raab Michael exercised 20,833 shares at a strike of $0.99 and sold $191,151 worth of shares (41,666 units at $4.59), decreasing direct ownership by 1% to 1,615,587 units (SEC Form 4)

      4 - ARDELYX, INC. (0001437402) (Issuer)

      4/8/25 7:24:24 PM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARDX
    Leadership Updates

    Live Leadership Updates

    See more
    • Ardelyx Appoints Merdad Parsey, M.D., Ph.D. to its Board of Directors

      WALTHAM, Mass., April 29, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced the appointment of Merdad Parsey, M.D., Ph.D. to the company's board of directors. "We are thrilled to welcome Merdad to our board of directors," said Mike Raab, president and chief executive officer of Ardelyx. "Merdad is a veteran biotech leader and clinician with a commitment to patients that aligns with the Ardelyx vision of a healthier tomorrow for patients. His broad leadership experience spans the entire pharmaceutical d

      4/29/25 8:00:00 AM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ardelyx Appoints Experienced Biopharma Executive, Eric Foster, as Chief Commercial Officer

      WALTHAM, Mass., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced the appointment of Eric Foster as the company's Chief Commercial Officer. Mr. Foster is an experienced leader with more than 23 years of commercial experience for significant global biotech and pharmaceutical companies across numerous complex rare disease and specialty markets. Mr. Foster will be responsible for leading all commercial strategies for the company's two first-in-class medicines, IBSRELA® (tenapanor) and XPHOZAH® (te

      8/8/24 8:00:00 AM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ardelyx Appoints Veteran BioPharma Executive, Mike Kelliher, as Executive Vice President, Corporate Development and Strategy

      WALTHAM, Mass., March 25, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced the appointment of Mike Kelliher to the position of Executive Vice President, Corporate Development and Strategy. Mr. Kelliher, an accomplished leader with more than 20 years of experience in the biopharmaceutical industry, brings to Ardelyx an extensive array of mergers and acquisitions, business development, strategy, finance and operational leadership expertise from leading biotechnology and global pharmaceutical companies.

      3/25/24 8:00:00 AM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care